Navigation Links
Avexa Reports Positive Phase IIb Result

VICTORIA, Australia--(BUSINESS WIRE)--Mar 20, 2007 - Australian biotechnology company Avexa (ASX:AVX) today announced highly successful results from its Phase IIb trial for apricitabine (ATC). ATC is Avexa's novel nucleoside reverse transcriptase inhibitor (NRTI) being developed for the treatment of HIV infection in patients with drug-resistant HIV.

The Phase IIb trial compared the effectiveness of ATC in reducing the viral load of patients with drug-resistant HIV with the effectiveness of lamivudine (3TC), a leading NRTI in widespread use. A total of 47 patients completed 21 day dosing. Of these 17 patients received 600 mg doses of ATC, 16 received 800 mg doses of ATC and the control group of 14 patients were treated with 3TC.

The results for patients in both ATC cohorts exceeded the Phase IIb trial primary endpoint by a substantial margin. Patients who received ATC achieved on average a reduction of greater than 0.8 log(10) (85%) in the level of HIV in the blood after 21 days treatment compared to a reduction of less than 0.03 log(10) in patients treated with 3TC. Nine patients achieved a greater than 1.5 log(10) (97%) reduction after 21 days, with 3 patients achieving a reduction of over 2.0 log(10) (99%). Remarkably, one patient achieved a decrease in the amount of virus of more than 2.5 log(10) (99.7%) after 21 days on ATC. Patients with the highest degree of drug resistance still achieved a significant benefit from treatment with ATC. The demonstration of superior activity in this study indicates that ATC will be an effective antiviral drug for the treatment of many drug-resistant patients, including even those most highly resistant.

"This is a fantastic result for Avexa," stated CEO Dr Julian Chick. "The positive result allows us to continue to progress ATC into Phase III trials and towards commercialisation. The team at Avexa has done a great job and these excellent results show that their
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Avexas Apricitabine Clinical Trial Update
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Avexa Reports Positive Phase IIb Result
(Date:4/24/2015)... , April 24, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, announced the Company will ... Tuesday, April 28, 2015 to discuss the 1st quarter ... listen to the call by dialing 1-888-346-3479. International participants ... should ask to be joined into the IGI Laboratories, ...
(Date:4/24/2015)...  Span-America Medical Systems, Inc. (NASDAQ:  SPAN) announced ... second quarter results on Thursday, April 30, after the ... will conduct a conference call at 10:00 a.m. ... financial and operating results for the second quarter ended ... conference call will be available online at ...
(Date:4/24/2015)... -- Introduction of new "Elements" ... for radiosurgery/SBRT   The "Elements" strategy ... the workflow for difficult to treat indications in ... comes full circle with the introduction of automated ... enable on-the-fly generation of consistent treatment plans for ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2
... Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its ... will be issued on Friday, November 5th at 6:30 ... 8:30 a.m. Friday, November 5th - 8:30 a.m. E.D.T.If ... callers use:502-719-4466Password - DUSAA replay of the call will ...
... BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial -- CARMIEL, Israel, Nov. 2, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 2Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 3Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 4Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 5Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 6Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 7Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 8Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 9Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 10
(Date:4/26/2015)... 2015 A live auction will be ... from hospitals, surgery centers and other medical facilities around ... sold including radiology, surgery, endoscopy, lab, anesthesia, exam and ... place Tuesday, April 28th starting at 10:00am EDT. The ... 5025 North Hiatus Rd., Sunrise, FL 33351. Anyone ...
(Date:4/26/2015)... 26, 2015 In an article published ... evaluated the head-neck biomechanics occurring during the use of handheld ... able to determine that use of a tablet increases mechanical ... 5 times - more than when the neck is in ... a study, but pointing out the potential hazards of overuse ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 MidSouth ... grow throughout the Southeast. MidSouth Pain Treatment Center is ... in Cordova, Southaven, Oxford and Jackson, two ambulatory surgery ... in the Southaven and Cordova locations. , Dr. ... ”I went into medicine to help people, and when ...
(Date:4/25/2015)... 2015 Avid Collector Andrew Hawley from ... Stones Greensboro Coliseum concert posters. The concert was held ... Stone's Second American Tour. , According to Hawley, ... of Baltimore, Maryland. This poster blank was used to ... cites. Globe uses garish lettering and colors on this ...
(Date:4/25/2015)... In the United States alone, an ... treatment for an illicit drug or alcohol ... Mental Health Services Administration’s Survey on Drug Use and ... are harrowing stories of men and women whose lives ... David H. Kerr , founder and retired president of ...
Breaking Medicine News(10 mins):Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Growing Pains for MidSouth Pain Treatment Center 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3
... Incorporated debuts Generation Max(TM) as students start back to ... driver Rudd celebrates 900th career start, HACKETTSTOWN, N.J., Sept. ... start at the California Speedway on,Sept. 2nd - a milestone ... this race, Rudd,s #88 Snickers(R) Ford Fusion will be outfitted,with ...
... other racial minorities have sleep durations associated with increased ... unhealthy sleep patterns among minorities long sleep or ... to a study published in the September 1 issue ... Lauren Hale, PhD, assistant professor in the graduate program ...
... Aug. 31 A recent government report shows ... million. The uninsured often,have limited access to preventive ... increasing the chance that avoidable medical,conditions will send ... that,can help people get the medicines prescribed by ...
... TOLEDO, Ohio, Aug. 31 Manor Care, Inc. (NYSE:,HCR) ... October 17,2007 as the date for a special meeting ... Care by an affiliate of global private equity,firm The ... the record,date for the meeting. On August 6, 2007, ...
... disease outbreaks, experts warn , , FRIDAY, Aug. 31 (HealthDay ... been remarkably successful, virtually eliminating diseases like measles and ... be appearing in the public health system that would ... are readily available. , That,s because a sizable segment ...
... (Amex: ZTM ), today announced that Gregory Halpern ... Release he signed on August,20, 2007. Under the ... three months, salary plus unused vacation and would have ... In addition, under,the Agreement the Company would have received ...
Cached Medicine News:Health News:Video: Nutrition Comes to NASCAR 2Health News:Video: Nutrition Comes to NASCAR 3Health News:Minorities more likely to have sleep durations associated with increased mortality 2Health News:Minorities more likely to have sleep durations associated with increased mortality 3Health News:Manor Care, Inc. Announces Record Date for Special Stockholder Meeting 2Health News:Growing Number of U.S. Kids Not Getting Needed Vaccinations 2Health News:Growing Number of U.S. Kids Not Getting Needed Vaccinations 3Health News:Growing Number of U.S. Kids Not Getting Needed Vaccinations 4Health News:Z Trim Announces Revocation of Gregory Halpern Severence Agreement 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: